{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T16:41:56Z","timestamp":1781282516919,"version":"3.54.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,4,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>There is in vitro and clinical evidence to suggest daptomycin has good activity against Enterococcus. In 2019, CLSI produced clinical breakpoints for Enterococcus spp.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe the distribution of MICs of daptomycin for enterococcal bloodstream infection (EBSI) isolates in a large Scottish health board, the indications for local daptomycin susceptibility testing and daptomycin doses used in vancomycin-resistant Enterococcus faecium (VREfm) infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We investigated all EBSIs over a 21\u2005month period and identified isolates tested against daptomycin. We recorded the distribution of MICs, as well as indications for daptomycin susceptibility testing and information on daptomycin dosing, where it was used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 293 blood culture isolates of Enterococcus spp., of which 37 had daptomycin susceptibility testing performed, from 31 individual patients. Of the 293 isolates, 103 were E. faecium, of which 63 were VREfm. Daptomycin testing was indicated by vancomycin resistance in 24\/37 isolates. All E. faecium isolates tested were in the CLSI \u2018susceptible dose-dependent (SDD)\u2019 range of MICs. All other Enterococcus spp. tested were in the \u2018susceptible\u2019 range. Twelve patients received daptomycin, and dosing information was recovered for 10. Nine of these patients received 8\u201312\u2005mg\/kg\/day dosing. There were no recorded adverse drug reactions. Ten of 12 patients were alive at the time of data collection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Daptomycin MIC distribution for EBSI isolates suggests a high local rate of susceptibility, according to CLSI breakpoints, in a population with high rates of VREfm. CLSI-recommended doses of daptomycin were used, with encouraging survival outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkac042","type":"journal-article","created":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T20:11:01Z","timestamp":1644005461000},"page":"1432-1435","source":"Crossref","is-referenced-by-count":4,"title":["Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant <i>Enterococcus faecium<\/i> (VREfm)"],"prefix":"10.1093","volume":"77","author":[{"given":"John","family":"Kelly","sequence":"first","affiliation":[{"name":"Medical Microbiology, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Tysall","sequence":"additional","affiliation":[{"name":"Medical Microbiology, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Dewar","sequence":"additional","affiliation":[{"name":"Medical Microbiology, Department of Laboratory Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"2022042812395773200_dkac042-B1","article-title":"Scottish One Health Antimicrobial use in Antimicrobial Resistance 2019","author":"Antimicrobial Resistance and Healthcare-related Infection (ARHAI) Scotland","year":"2021"},{"key":"2022042812395773200_dkac042-B2","article-title":"Antimicrobial resistance in the EU\/EEA (EARS-Net) - Annual Epidemiological Report for 2019","author":"ECDC","year":"2020"},{"key":"2022042812395773200_dkac042-B3","first-page":"768","article-title":"Vancomycin resistant enterococci: a brief review","volume":"68","author":"Raza","year":"2018","journal-title":"J Pak Med Assoc"},{"key":"2022042812395773200_dkac042-B4","doi-asserted-by":"crossref","first-page":"e00506-18","DOI":"10.1128\/AAC.00506-18","article-title":"Pharmacodynamics of daptomycin against Enterococcus faecium and Enterococcus faecalis in the murine thigh infection model","volume":"62","author":"Kidd","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812395773200_dkac042-B5","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1093\/cid\/ciy749","article-title":"Pharmacodynamic analysis of daptomycin-treated enterococcal bacteremia: it is time to change the breakpoint","volume":"68","author":"Avery","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2022042812395773200_dkac042-B6","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2014Twenty-ninth Edition: M100","author":"CLSI","year":"2019"},{"key":"2022042812395773200_dkac042-B7","first-page":"1240","article-title":"Development of daptomycin susceptibility breakpoints for Enterococcus faecium and revision of the breakpoints for other enterococcal species by the Clinical and Laboratory Standards Institute","volume":"70","author":"Satlin","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022042812395773200_dkac042-B8","doi-asserted-by":"crossref","first-page":"e00600-19","DOI":"10.1128\/JCM.00600-19","article-title":"The new, new daptomycin breakpoint for Enterococcus spp","volume":"57","author":"Humphries","year":"2019","journal-title":"J Clin Microbiol"},{"key":"2022042812395773200_dkac042-B9","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/jac\/dkq087","article-title":"A potential role for daptomycin in enterococcal infections: what is the evidence?","volume":"65","author":"Cant\u00f3n","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2022042812395773200_dkac042-B10","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.cmi.2020.04.027","article-title":"Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper","volume":"26","author":"Turnidge","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2022042812395773200_dkac042-B11","doi-asserted-by":"crossref","first-page":"e00745-18","DOI":"10.1128\/AAC.00745-18","article-title":"Variability of daptomycin MIC values for Enterococcus faecium when measured by reference broth microdilution and gradient diffusion tests","volume":"62","author":"Campeau","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812395773200_dkac042-B12","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812395773200_dkac042-B13","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1128\/AAC.00247-06","article-title":"Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers","volume":"50","author":"Benvenuto","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2022042812395773200_dkac042-B14","first-page":"605","article-title":"Comparative effectiveness and safety of standard-, medium-, and high-dose daptomycin strategies for the treatment of vancomycin-resistant enterococcal bacteremia among Veterans Affairs patients","volume":"64","author":"Britt","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2022042812395773200_dkac042-B15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/cid\/cix024","article-title":"Effect of daptomycin dose on the outcome of vancomycin-resistant, daptomycin-susceptible Enterococcus faecium bacteremia","volume":"64","author":"Chuang","year":"2017","journal-title":"Clin Infect Dis"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/5\/1432\/43480532\/dkac042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/77\/5\/1432\/43480532\/dkac042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T12:41:27Z","timestamp":1651149687000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/77\/5\/1432\/6528651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,2,15]]},"published-print":{"date-parts":[[2022,4,27]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkac042","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,5,1]]},"published":{"date-parts":[[2022,2,15]]}}}